PPAR-α and PPAR-γ agonists for type 2 diabetes

The Lancet

Volumn 374, Issue 9684, 2009, Pages 96-98

  Charbonnel, Bernard ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TESAGLITAZAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LIPID METABOLISM; METABOLISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 67649852314     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61040-0     Document Type: Note

References (15)

1. Henry R.R., Lincoff A.M., Mudaliar S., Rabbia M., Chognot C., and Herz M. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet (2009) 10.1016/S0140-6736(09)60870-9 published online June 8.
2. Kahn S.E. Glucose control in type 2 diabetes. Still worthwhile and worth pursuing. JAMA 301 (2009) 1590-1592
3. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009) 1765-1772
4. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
5. Balakumar P., Rose M., Ganti S., Krishan P., and Singh M. PPAR dual agonists: are they opening Pandora's box?. Pharmacol Res 56 (2007) 90-98
6. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
7. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
8. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
9. Rajamani K., Colman P.G., Li L.P., et al., on behalf of the FIELD study investigators. Effect of a fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373 (2009) 1780-1788
10. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
11. Fievet C., Fruchard J.C., and Staels B. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6 (2006) 606-614
12. Rubenstrunk A., Hanf R., Hum D., Fruchart J.C., and Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771 (2007) 1065-1081
13. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes. JAMA 294 (2005) 2581-2586
14. Bénardeau A., Benz J., Binggeli A., et al. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 19 (2009) 2468-2473
15. Gelman L., Neige J., and Desvergne B. Molecular basis of selective PPAR modulation for the treatment of type 2 diabetes. Biochim Biophys Acta 1771 (2007) 1094-1107